Maxygen Gets $90 Million Cash Infusion From Bayer For Hemophilia Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal will build on Bayer’s hemophilia experience with Kogenate, and provide cash for Maxygen to explore autoimmune programs.
You may also be interested in...
Maxygen And Astellas Form Joint Venture, Combining Cash And Staff
Three senior execs will depart in a deal that could result in a staged acquisition of the J/V by the Japanese pharma.
Maxygen And Astellas Form Joint Venture, Combining Cash And Staff
Three senior execs will depart in a deal that could result in a staged acquisition of the J/V by the Japanese pharma.
Maxygen “Confident” About MAXY-4 Patents – Astellas, Too
Deal with transplant-drug firm shows faith that Repligen/BMS-like skirmish not in the cards.